Home > Resources > Company Profiles > Targacept, Incorporated

Targacept, Incorporated (TRGT)

EMAIL
PRINT
SHARE
TEXT SIZE:
SHARE
Send a copy to me

Separate multiple email addresses (max 20) with commas.

0/1500
Dr. J. Donald deBethizy, Ph.D. , CEO/President/Director
Industry: Healthcare
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME


Overview
News
People
Financials

Company Information

Dr. J. Donald deBethizy, Ph.D., CEO/President/Director

200 East First Street

Suite 300

Winston-Salem, NC 27101

US Map it

Phone: (336) 480-2100

Fax: (336) 480-2107

www.targacept.com

Latest news from Portfolio


Overview

A biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics(tm), a new class of drugs for the treatment of multiple diseases and disorders of the central nervous system.

Portfolio Articles
  • The Ultimare Cure
    The neurotech industry is engaged in a $2 trillion race to fix your brain. Many players will fail, but the payoff will be huge for those who succeed.
    May 12 2008

See more news on this company

Employees

Number of Employees: 100
Revenue per Employee: $379,128

Top Executives

Dr.Geoffrey C. Dunbar, M.D., Divisional Vice President
Peter A. Zorn, Divisional Vice President/General Counsel/Secretary
Jeffrey P. Brennan, Divisional Vice President

Alan A. Musso, CPA, CFO/Vice President/Treasurer/Assistant Secretary
Dr. William S. Caldwell, Ph.D., Divisional Vice President
Dr.Merouane Bencherif, M.D., Ph.D., Divisional Vice President

Board of Directors

Mark Skaletsky, Chairman of the Board/Director
Peter A. Zorn, Divisional Vice President/General Counsel/Secretary
Julia R. Brown, Director

Alan A. Musso, CPA, CFO/Vice President/Treasurer/Assistant Secretary
Charles A. Blixt, Director
Dr.Errol B. De Souza, Ph.D., Director

Financials

Quarterly
Annual

Income Statement 08/2008 05/2008 03/2008 12/2007
Sales -281.2 K. -173.95 K. -99.06 K. -44.86 K.
Gross Operating Profit 5.44 Mil. 4.45 Mil. 3.66 Mil. 3.17 Mil.
Operating Income before D & A (EBITDA) -6.97 Mil. -6.32 Mil. -8.38 Mil. -8.19 Mil.
Total Income Before Interest Expenses (EBIT) -6.73 Mil. -5.73 Mil. -7.6 Mil. -7.32 Mil.
Total Net Income -6.8 Mil. -5.78 Mil. -7.65 Mil. -7.37 Mil.
Basic EPS, Total -0.27 -0.24 -0.37 -0.37
Diluted EPS, Total -0.27 -0.24 -0.37 -0.37

BALANCE STATEMENT 08/2008 05/2008 03/2008 12/2007
Cash and Equivalents 64.37 Mil. 65.47 Mil. 53.4 Mil. 51.87 Mil.
Total Assets 106.83 Mil. 97.53 Mil. 92.41 Mil. 93.89 Mil.
Total Liabilities 14.09 Mil. 13.59 Mil. 15.2 Mil. 11.73 Mil.
Total Capitalization 72.98 Mil. 79.23 Mil. 53.27 Mil. 60.46 Mil.

Cash Flow 08/2008 05/2008 03/2008 12/2007
Net Cash From Continuing Operations -15.14 Mil. -6.72 Mil. 24.84 Mil. 24.88 Mil.
Net Cash From Investing Activities -5.63 Mil. -13.29 Mil. -26.29 Mil. -27.85 Mil.
Net Cash From Financing Activities 31.73 Mil. 32.08 Mil. 13.11 Mil. 13.1 Mil.
Net Change in Cash & Cash Equivalents 10.96 Mil. 12.06 Mil. 11.66 Mil. 10.13 Mil.

powered by Interactive Data

Income Statement 2008 2007 2006
Sales -191.74 K. -363.67 K. -322.25 K.
Gross Operating Profit 11.77 Mil. 27.9 Mil. 1.5 Mil.
Operating Income before D & A (EBITDA) -30.86 Mil. 417.23 K. -29.14 Mil.
Total Income Before Interest Expenses (EBIT) -27.93 Mil. 2.18 Mil. -28.77 Mil.
Total Net Income -28.07 Mil. 2.1 Mil. -28.99 Mil.
Basic EPS, Total -1.42 -0.09 -153.54
Diluted EPS, Total -1.42 -0.09 -153.54

BALANCE STATEMENT 2008 2007 2006
Cash and Equivalents 53.4 Mil. 41.74 Mil. 24.85 Mil.
Total Assets 92.41 Mil. 78.85 Mil. 25.74 Mil.
Total Liabilities 15.2 Mil. 8.95 Mil. 5.21 Mil.
Total Capitalization 53.27 Mil. 65.81 Mil. -161.07 Mil.

Cash Flow 2008 2007 2006
Net Cash From Continuing Operations 24.84 Mil. -9.89 Mil. -26.25 Mil.
Net Cash From Investing Activities -26.29 Mil. -13.27 Mil. -250.25 K.
Net Cash From Financing Activities 13.11 Mil. 40.05 Mil. -1.73 Mil.
Net Change in Cash & Cash Equivalents 11.66 Mil. 16.89 Mil. -28.22 Mil.

powered by Interactive Data







Related Companies by Market Cap
Company Name
Price
Change
Market Cap
Pharmacopeia, Incorporated
144.52 Mil.
ImmunoGen, Incorporated
146.24 Mil.
Vical, Incorporated
147.37 Mil.
Trimeris, Incorporated
149.13 Mil.

Company Profile Change Request

The data provided in our company profiles comes from third party information providers.

Also in Portfolio.com
Most Read
Most Emailed
Recently Commented